Weekly Journal Scan: Less-than- OPTIMAl evidence for a shorter duration of dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation
- 14 November 2026
- journal article
- Published by Oxford University Press (OUP) in European Heart Journal
Abstract
No abstract availableThis publication has 12 references indexed in Scilit:
- 1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): a multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trialThe Lancet, 2026
- Aspirin in Patients with Chronic Coronary Syndrome Receiving Oral AnticoagulationNew England Journal of Medicine, 2025
- Edoxaban Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Artery DiseaseNew England Journal of Medicine, 2024
- Intravascular imaging-guided coronary drug-eluting stent implantation: an updated network meta-analysisThe Lancet, 2024
- Clinical Significance of Atrial Fibrillation Status in Patients With Percutaneous Coronary InterventionCJC Open, 2021
- Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary DiseaseNew England Journal of Medicine, 2019
- Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial FibrillationNew England Journal of Medicine, 2019
- Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial FibrillationNew England Journal of Medicine, 2017
- World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCINature Reviews Cardiology, 2014
- Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trialThe Lancet, 2013